Independent investment research firm, Bioshares, rated Patrys as one of its top six stock picks for 2021, stating: ‘In general, antibodies are unable to cross the blood-brain barrier, so an antibody that overcomes that limitation, along with the potential to hit a key target, such as one related to glioblastoma (a brain cancer), is significant. Patrys is in the possession of a potentially powerful new approach for addressing difficult-to-treat cancers, such as brain, melanoma, breast, prostate and ovarian cancers.’
